Funding Tracker/Specific Biologics
Series A · Pharma & Drug Discovery · Canada
Specific Biologics raises $35M
Announced November 2, 2026
The round
Specific Biologics announced a Series A round of $35M on November 2, 2026, led by Hatteras Venture Partners. Other participants include Lumira Ventures, adMare BioInnovations, Genesys Capital, BDC Life Sciences Venture Fund, DeepWork Capital, Seido Capital.
The SignalOversubscribed US$35 million Series A to advance Dualase toward initial biomarker proof-of-concept in an adaptive Phase I/II trial for C9ORF72-associated ALS. This is a development plan, not evidence of established clinical benefit.
- Company
- Specific Biologics
- Amount
- $35M
- Stage
- Series A
- Announced
- November 2, 2026
- Led by
- Hatteras Venture Partners
- Other investors
- Lumira Ventures, adMare BioInnovations, Genesys Capital, BDC Life Sciences Venture Fund, DeepWork Capital, Seido Capital
- Vertical
- Pharma & Drug Discovery
- Country
- Canada